Valneva SE (INRLF)

Market Cap	496.89M
Revenue (ttm)	201.10M
Net Income (ttm)	-86.89M
Shares Out	n/a
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	36
Open	3.250
Previous Close	3.100
Day's Range	3.100 - 3.250
52-Week Range	1.880 - 4.060
Beta	1.09
RSI	27.46
Earnings Date	Aug 12, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 713
• Stock Exchange: OTCMKTS
• Ticker Symbol: INRLF

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.

Financial numbers in EUR